Charles Oschwald, MD
Cardiovascular Disease · Johnstown, PANPI 1548291214
Payments from drug & device makers
Across 382 payments — averaging $176.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$42K
- Amgen$17K
- Esperion Therapeutics, Inc.$4K
- Abbott$2K
- Novartis$526
- Amarin Pharma, Inc.$494
- plus $2K from 22 others
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$51,47276%
- Travel & lodging$8,13612%
- Food & beverage$7,19011%
- Education$2280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 121 | $42,117 |
| Amgen | 74 | $16,990 |
| Esperion Therapeutics, Inc. | 11 | $3,900 |
| Abbott | 21 | $1,703 |
| Novartis | 31 | $526 |
| Amarin Pharma, Inc. | 33 | $494 |
| AstraZeneca | 7 | $257 |
| Merck | 13 | $189 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $156 |
| E.r. Squibb & Sons, L.L.C. | 9 | $138 |
| Boehringer Ingelheim | 9 | $136 |
| Boston Scientific | 3 | $121 |
| Pfizer | 6 | $86 |
| Sanofi-aventis U.S. LLC | 7 | $85 |
| Alnylam Pharmaceuticals Inc. | 4 | $67 |
| Daiichi Sankyo Inc. | 2 | $49 |
| Preventice Services, LLC | 3 | $46 |
| Abiomed | 2 | $43 |
| Vifor Pharma, Inc. | 2 | $37 |
| Irhythm Technologies, Inc. | 2 | $34 |
| Tactile Systems Technology Inc | 2 | $32 |
| Bayer | 1 | $20 |
| Atricure, Inc. | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| Novo Nordisk | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
| Bardy Diagnostics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$40,429
- Repatha$15,857
- NEXLETOL$3,731
- NEXLIZET$3,731
- Confirm Rx$570
- QUADRA ASSURA$132
- Allure Quadra RF CRT Pacemaker$112
- GALLANT$112
- AVEIR$100
How this compares
$67,326 in reported general payments places this provider in the 90th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 493 | $477,276 |
| EntrestoSacubitril/Valsartan | 155 | $228,977 |
| EliquisApixaban | 144 | $161,562 |
| Repatha SureclickEvolocumab | 106 | $130,453 |
| BrilintaTicagrelor | 82 | $69,452 |
| Repatha PushtronexEvolocumab | 75 | $55,658 |
| FarxigaDapagliflozin Propanediol | 30 | $41,326 |
| MultaqDronedarone Hcl | 23 | $22,793 |
| Ezetimibe | 454 | $14,665 |
| Atorvastatin Calcium | 778 | $13,845 |
| Metoprolol Succinate | 344 | $6,476 |
| Icosapent Ethyl | 21 | $5,684 |
| Rosuvastatin Calcium | 194 | $5,116 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 336 | $5,077 |
| Metoprolol Tartrate | 426 | $4,899 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $42,117 | $477,276493 claims |
| NovartisEntresto | $526 | $228,977155 claims |
| PfizerEliquis | $86 | $161,562144 claims |
| AstraZenecaBrilinta, Farxiga | $257 | $110,779112 claims |
| Sanofi-aventis U.S. LLCMultaq | $85 | $22,79323 claims |
| Boehringer IngelheimPradaxa | $136 | $2,00311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Other cardiovascular disease in Johnstown
- Danielle DuffyPhiladelphia$29.5M
- Venkatesh NadarCamp Hill$18.3M
- Hemal GadaWormleysburg$6.7M
- Brian DrachmanPhiladelphia$3.8M
- William BachinskyMechanicsburg$2.3M
- Bonnie KyPhiladelphia$1.9M
- Benjamin KalsmithPgh$1.7M
- Marielle Scherrer CrosbiePhiladelphia$1.6M
- Paul GrenaYardley$1.6M
- Peter KoweyWynnewood$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.